ProCE Banner Events


AL Amyloidosis: Advancements and Future Trends on Diagnosis and Individualized Treatment Approaches

Register now for this satellite symposium held in conjunction with the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California, featuring expert discussions on timely and optimal diagnosis of AL amyloidosis, management of newly diagnosed and relapsed/refractory disease, and supportive management of AL amyloidosis symptoms.  At the end of the session, experts will answer pressing audience questions in a live Q&A session.

Physicians: maximum of 2.00 AMA PRA Category 1 Credits™

This event has expired. No longer available for credits.

Who Should Attend

This program is intended for physicians and other healthcare professionals who care for patients with AL amyloidosis.

Time and location

Friday, December 08, 2023

3:30 PM - 5:30 PM Pacific Time (PT)


Marriott Marquis San Diego Marina
333 W Harbor Dr.
San Diego, California 92101

Pacific Ballroom 21-22

Angela Dispenzieri, MD

Division of Hematology
Serene M. and Frances C. Durling Professor of Medicine and of Laboratory Medicine 
Mayo Clinic
Rochester, Minnesota 

Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM

Professor of Medicine and Haematology
University College London
Honorary Consultant Haemetologist
University College Hospitals
Director, Jack O’Neil Laboratory
Department of Haematology
National Amyloidosis Centre
London, United Kingdom


Registration & Refreshment: 3:00 PM - 3:30 PM PT

  • Biology, clinical presentation, and diagnostic approach for AL amyloidosis
  • Overview of recent treatment guidelines 
  • Current/evolving management algorithm for patients with newly diagnosed AL amyloidosis
  • Current/evolving algorithm for the management of AL amyloidosis at relapse
  • Clinical trial spotlight and review of key abstracts to be presented at ASH 2023


Venue Name

Marriott Marquis San Diego Marina


Marriott Marquis San Diego Marina
333 W Harbor Dr.
San Diego, California 92101

Room Name

Pacific Ballroom 21-22


Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare professionals to optimize diagnosis and management of patients with AL amyloidosis.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with AL amyloidosis.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply current evidence and guideline recommendations for the diagnosis and management of AL amyloidosis via urgent biopsy and accurate precursor protein typing
  • Integrate into practice up-to-date efficacy and safety data on currently available and novel therapies to treat newly diagnosed and relapsed/refractory AL amyloidosis based on accurate risk and response assessment
  • Appraise ongoing clinical trials evaluating promising novel therapy for the treatment of patients with AL amyloidosis
  • Implement evidenced-based supportive measures for patients with AL amyloidosis that improve quality of life, relieve symptoms, and sustain organ function


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 


Provided by Clinical Care Options, LLC

Supported by educational grants from Alexion Pharmaceuticals; Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC; and Prothena Biosciences Limited.

Contact Information

For customer support please click here.

Mailing Address:


Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact prior to the live event.